Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1994-06-17
1996-11-05
Smith, Lynette R. F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4242041, 4242341, 530350, A61K 3921, A61K 3912, C07K 100, C07K 1400
Patent
active
055715150
ABSTRACT:
Improved vaccine compositions and methods of making the compositions are provided, which vaccines are characterized by an antigen from a pathogen and an effective adjuvanting amount of Interleukin-12 (IL-12). These IL-12 adjuvanted vaccines are capable of increasing the vaccinated host's cell mediated immune response to provide an increased and protective immune response to the pathogen. Also disclosed are methods for vaccinating hosts by administering a vaccine containing an antigen from a pathogenic microorganism and co-administering an adjuvanting amount of IL-12. Vaccines or therapeutic compositions directed against a cancer may also be adjuvanted with IL-12 according to this invention.
REFERENCES:
Hentges, (Ed.), 1986, Medical Microbiology: A Review With Questions and Explanations, pp. 14-18, 25-29, 206-209, 286-287.
Kurth, et al, 1991, "The Quest for an AIDS Vaccine . . . " AIDS Res. Hum. Retroviruses 7(5):425-433.
Butcher, 1989, "Mechanisms of Immunity to Malaria . . . " Parasitology 98:315-327.
Greene, 1993, "AIDS and the Immune System" Scientific American Sep. 1993, pp. 99-105.
Freeman, et al, 1989, "B7, A New Member of the . . . " J. Immunol. 143:2714-2722.
Jerome, et al, 1993, "Tumor-Specific Cytotoxic T Cell . . . " J. Immunol. 151(3):1654-1662.
T. Mosmann et al, "Two Types of Murine Helper T Cell Clone", J. Immunol., 136(7):2348-2357 (Apr. 1, 1986).
H. Warren et al, "Current Status of Immunological Adjuvants", Ann. Rev. Immunol., 4:369-388 (Apr. 1986).
A. D'Andrea et al, "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells", J. Exp. Med., 176:1387-1398 (Nov., 1992).
M. Kobayashi et al, "Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), a Cytokine with Multiple Biologic Effects on Human Lymphocytes", J. Exp. Med., 170:827-845 (Sep., 1989).
S. Chan et al, "Induction of Interferon gamma Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers", J. Exp. Med., 173:869-879 (Apr., 1991).
F. Heinzel et al, "Recombinant Interleukin 12 Cures Mice Infected with Leishmania Major", J. Exp. Med., 177:1505-1509 (May, 1993).
J. Sypek et al, "Resolution of Cutaneous Leishmaniasis: Interleukin 12 Initiates a Protective T Helper Type 1 Immune Response", J. Exp. Med., 177:1797-1802 (Jun., 1993).
A. McKnight et al, "Effects of IL-12 on Helper T Cell-Dependent Immune Responses in vivo", J. Immunol., 152:2172-2179 (Jun., 1994).
L. Afonso et al, "The Adjuvant Effect of Interleukin--12 in a Vaccine Against Leishmania Major", Science, 263:235-237 (Jan. 14, 1994).
C-S. Hsieh et al, "Development of TH1 CD4+ T Cells Through IL--12 Produced by Listeria-Induced Macrophages", Science, 260:547-549 (Apr. 23, 1993).
P. Scott, "IL--12: Initiation Cytokine for Cell-Mediated Immunity", Science 260:496-497 (Apr. 23, 1993).
R. Manetti et al, "Natural Killer Cell Stimulatory Factor (Interleukin 12 [IL--12]) Induces T Helper Type 1 (Th1)-Specific Immune Responses and Inhibits the Development of IL-4-Producing Th Cells", J. Exp. Med., 177:1199-1204 (Apr. 1993).
Scott Phillip
Trinchieri Giorgio
Smith Lynette R. F.
The Trustees of the University of Pennsylvania
The Wistar Institute of Anatomy & Biology
LandOfFree
Compositions and methods for use of IL-12 as an adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for use of IL-12 as an adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for use of IL-12 as an adjuvant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2013231